Your browser doesn't support javascript.
loading
Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy.
Murakami, Naoya; Asami, Yuka; Yoshida, Hiroshi; Takayanagi, Daisuke; Hirose, Sou; Kuno, Ikumi; Takahashi, Kazuaki; Matsuda, Maiko; Shimada, Yoko; Yamano, Shotaro; Sunami, Kuniko; Honda, Takayuki; Nakahara, Tomomi; Watanabe, Tomoko; Okuma, Kae; Kuroda, Takafumi; Kohno, Takashi; Kato, Tomoyasu; Shiraishi, Kouya; Itami, Jun.
Afiliação
  • Murakami N; Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. namuraka@ncc.go.jp.
  • Asami Y; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Yoshida H; Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan.
  • Takayanagi D; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Hirose S; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Kuno I; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Takahashi K; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Matsuda M; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Shimada Y; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Yamano S; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Sunami K; Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan.
  • Honda T; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Nakahara T; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Watanabe T; Division of Carcinogenesis and Cancer Prevention, Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
  • Okuma K; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Kuroda T; Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Kohno T; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Kato T; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Shiraishi K; Department of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Itami J; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kshirais@ncc.go.jp.
Sci Rep ; 11(1): 10567, 2021 05 19.
Article em En | MEDLINE | ID: mdl-34012039
ABSTRACT
Somatic genetic alteration analysis was performed for post-hysterectomy high-risk early-stage uterine cervical cancer patients who underwent post-operative radiation therapy. Post-operative radiation therapy was performed for patients with pathological features of pelvic lymph node metastasis, parametrium invasion, or positive vaginal margin, which corresponded to the post-operative high-risk category. DNA was extracted from paraffin-embedded surgical specimens, and 50 somatic hotspot genetic alternations were detected using Ion AmpliSeq Cancer Hotspot Panel. The existence of actionable mutation was assessed based on OncoKB evidence level > 3A. Between January 2008 and November 2019, 89 patients who underwent abdominal radical hysterectomy followed by post-operative radiation therapy were identified. The follow-up period for living patients was 82.3 months (range 9.3-153.9), and the 5-year relapse-free survival and overall survival rates were 72.6% and 85.9%, respectively. The most frequently detected somatic mutation was PIK3CA (26 [29.2%] patients); however, no prognostic somatic genetic alterations were identified. Actionable mutations were detected in 30 (33.7%) patients. Actionable mutations were detected in approximately one-third of patients, suggesting that precision medicine can be offered to patients with post-operative high-risk uterine cervical cancer in the near future.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Proteína Supressora de Tumor p53 / Proteínas Serina-Treonina Quinases / PTEN Fosfo-Hidrolase / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Colo do Útero / Proteína Supressora de Tumor p53 / Proteínas Serina-Treonina Quinases / PTEN Fosfo-Hidrolase / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão